Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iSTOP: SBRT + Intermittent Hormone Therapy in Oligometastatic Prostate Cancer
NCT04619069Phase 2Active, not recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Oct 2020
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Proportion of eligible patients who enroll onto the study at 2 years. Started Oct 2020; status: active, not recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04619069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619069.